Wainman Paul R 4

What Happened

• Paul R. Wainman, a director of Immucell Corp. (ICCC), was awarded a derivative grant on April 16, 2025 covering 10,000 shares. The Form 4 reports the acquisition price as $0 (i.e., an option/award rather than a cash purchase). The issuer notes the grant was made to compensate directors for board services.

Key Details

• Transaction date: 2025-04-16; reported on Form 4 filed 2026-04-14 (appears to be a late filing).
• Transaction type: Award/Grant (derivative option award) for 10,000 shares; reported acquisition price $0.
• Reported value: $0 at grant on the Form 4 (this reflects how the award is recorded, not necessarily economic value or exercise terms).
• Shares owned after transaction: Not specified in the provided filing details.
• Notable footnote: Issuer statement specifies the options were granted as director compensation.
• Timeliness: Filing was submitted nearly a year after the report date; late filings reduce transparency and can be of regulatory concern.

Context

• This was an equity-based compensation award to a director (not an open-market purchase or sale). Such grants are routine for board compensation and do not, by themselves, indicate the director bought or sold company stock.
• Because this is a derivative award (options), it does not represent immediate ownership of stock until exercised; check the company’s subsequent filings for exercise terms, strike price, vesting schedule, or any later exercises/sales.